2,774 Shares in Icon Plc $ICLR Acquired by DAVENPORT & Co LLC

Key Points

• DAVENPORT & Co LLC acquired 2,774 shares of Icon Plc for approximately $403,000 in the second quarter, according to their 13F filing with the SEC.
• Analysts have issued varied ratings for Icon Plc, with UBS raising their price target to $240.00 and maintaining a "buy" rating, while Citigroup set a target at $200.00 with a "neutral" rating.
• Icon Plc's stock price decreased by 2.2%, with a current share price of $183.49 and a market capitalization of $14.82 billion.

DAVENPORT & Co LLC bought a new position in shares of Icon Plc (NASDAQ:ICLR - Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 2,774 shares of the medical research company's stock, valued at approximately $403,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Farther Finance Advisors LLC raised its holdings in shares of Icon by 22.8% during the 1st quarter. Farther Finance Advisors LLC now owns 593 shares of the medical research company's stock valued at $99,000 after purchasing an additional 110 shares in the last quarter. Wealthquest Corp acquired a new stake in Icon in the 1st quarter worth $862,000. Transcend Capital Advisors LLC grew its position in Icon by 7.6% in the 1st quarter. Transcend Capital Advisors LLC now owns 1,174 shares of the medical research company's stock worth $205,000 after purchasing an additional 83 shares during the last quarter. Cloud Capital Management LLC bought a new position in shares of Icon during the 1st quarter worth about $101,000. Finally, Whittier Trust Co. lifted its holdings in shares of Icon by 9.2% during the 1st quarter. Whittier Trust Co. now owns 5,172 shares of the medical research company's stock worth $905,000 after acquiring an additional 436 shares during the period. Hedge funds and other institutional investors own 95.61% of the company's stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on ICLR shares. UBS Group lifted their price target on shares of Icon from $170.00 to $240.00 and gave the company a "buy" rating in a report on Friday, July 25th. Barclays boosted their price objective on shares of Icon from $180.00 to $190.00 and gave the company an "equal weight" rating in a report on Thursday, October 2nd. Citigroup reiterated a "neutral" rating and issued a $200.00 price target (down previously from $225.00) on shares of Icon in a report on Thursday, August 21st. Truist Financial boosted their price objective on shares of Icon from $187.00 to $234.00 and gave the stock a "buy" rating in a research report on Friday, July 25th. Finally, Rothschild & Co Redburn raised shares of Icon from a "neutral" rating to a "buy" rating and upped their price target for the stock from $184.00 to $236.00 in a research report on Wednesday, September 3rd. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $217.33.

Icon Stock Down 2.2%

ICLR stock opened at $183.49 on Monday. The stock has a market capitalization of $14.82 billion, a P/E ratio of 18.88, a price-to-earnings-growth ratio of 2.72 and a beta of 1.23. The company has a current ratio of 1.29, a quick ratio of 1.29 and a debt-to-equity ratio of 0.35. Icon Plc has a 12 month low of $125.10 and a 12 month high of $301.45. The firm has a 50-day moving average price of $174.56 and a 200-day moving average price of $156.71.

Icon (NASDAQ:ICLR - Get Free Report) last posted its earnings results on Wednesday, July 23rd. The medical research company reported $3.26 EPS for the quarter, topping analysts' consensus estimates of $3.18 by $0.08. The firm had revenue of $2.02 billion during the quarter, compared to analysts' expectations of $1.98 billion. Icon had a net margin of 9.82% and a return on equity of 10.95%. The business's revenue for the quarter was down 4.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.75 earnings per share. Icon has set its FY 2025 guidance at 13.000-14.000 EPS. As a group, equities research analysts anticipate that Icon Plc will post 13.38 EPS for the current fiscal year.

About Icon

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

Want to see what other hedge funds are holding ICLR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Icon Plc (NASDAQ:ICLR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.